The UK company reveals the results from a partner-led survey to discover the rates ... examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID ...

Valisure's 'qui tam' lawsuit saw the drug testing company sue GSK as a whistleblower on behalf of the U.S. government over claims the British firm led a "campaign of deception" to hide the fact ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

led to a one-day 6 billion pound drop in GSK’s market cap. The report adds that investors are now shifting their focus to GSK’s broader performance and long-standing concerns about its drug ...

The update on the GSK-partnered prospect sent Wave’s share ... However, the limitations of those treatments have led companies including Takeda and Vertex to move AATD candidates into and ...

In the complaint, GSK argues Pfizer kicked off the project that led to Abrysvo no earlier than 2013, which it claims was at least seven years after its own RSV program. Up until recently ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... this quarter with growth up 7% led by another outstanding performance ...

23andme has been the poster child of a boom in consumer DNA ... when it was valued at almost $6bn (£4.6bn). GlaxoSmithKline, ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.